科研之友
微信
新浪微博
Facebook
分享链接
摘要
this paper pretends to identify the ethical criteria established in certain countries with uptodate norms on biodisponibility/bioequivalence, and to determine if such criteria really protect participants in these investigations. in order to obtain information a questionnaire on biodisponibility/bioequivalence topics was sent via email to the medicaments＊ regulating agencies in argentina, bolivia, brasil, chile, colombia, costa rica, ecuador, m谷xico, paraguay, per迆, uruguay and venezuela. conclusions show that uptodate norms regarding necessary ethical aspects to protect people who participate in those investigations are unequal ethical requirements should be uniformed so as to allow a quicker legislation development in those countries that still lack it. this would also strengthen the region＊s pharmacaeutical regulations
